Clinical Trial Update: XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating XRP9881 in combination with trastuzumab for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)
• XRP9881 (XRP9881)

Snippet

Sponsor: Sanofi | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED